Evidence Hub

Statins Enhance the Efficacy of Pegylated Interferon-alpha2 in Patients with Ph-Negative Chronic Myeloproliferative Neoplasms. Results from a Danish Single-Institution Cohort Study

I. Hansen, M. K. Larsen, V. Skov, Lasse Kjær, Christina Ellervik, A. Sørensen, T. Knudsen, S. Christensen et al.

Blood, 2024

126 participants · 1 citation

Abstract

Background: Chronic inflammation is an important driving force in the development and progression of myeloproliferative neoplasms (MPNs) in the biological continuum from the early MPN-stages - essential thrombocythemia (ET) and polycythemia vera (PV) - to the advanced myelofibrotic stage (MF). Statins are cholesterol-lowering drugs used for primary and secondary prevention of cardiovascular disease. In addition to cholesterol reduction, statins have demonstrated anti-proliferative, proapoptotic, anti-angiogenic, and anti-inflammatory properties. Several studies have investigated their impact on various types of cancer, including MPNs, demonstrating a reduction in the risk of cancer development and all-cause mortality. These pleiotropic effects of statins might be beneficial in the treatment of MPNs.

Aim: We aimed to investigate if statin use, in addition to standard cytoreductive treatment, entails a shorter time to obtain hematological and molecular responses, and with a lower dosage of cytoreductive drugs.

Method: The study was a single-institution, retrospective cohort study. We investigated a cohort of 126 patients diagnosed with MPNs at the Department of Hematology at Zealand University Hospital in Denmark from 2010-2023, including a JAK2V617F-subgroup consisting of all IFN-treated patients with the JAK2V617F mutation and ≥ 2 JAK2V617F variant allele frequency measurements (n = 34). All patients were diagnosed according to the WHO 2008 or 2016 classification of MPN.…

How strong is the evidence?

Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 126 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free